CEimpact Podcast

The American Diabetes Association has released the 2024 Standards of Care for people with Type 1 and Type 2 Diabetes. Join us as we talk with one of our favorite diabetes experts, Dr. Sue Cornell, about the major shifts in diabetes care that are omnipresent in this year's guideline updates.
 
The GameChanger
Diabetes treatment is shifting to prevention and delay. After a long period of time without many advances, we are now on the brink of changing the game in diabetes care and prevention with new drugs and technologies.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Susan Cornell, PharmD, CDCES, FAPhA, FADCES
Diabetes Care & Education Specialist
Midwestern University College of Pharmacy
 
Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss highlights of the 2024 American Diabetes Association Standards of Care Update
2. Describe the landscape of diabetes care as it shifts to prevention and delay

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-050-H01-P
Initial release date: 2/5/2024
Expiration date: 2/5/2025
Additional CPE details can be found here.

Join us Tuesday, February 13th from 7-9pm for our next live course:
From A1C to Z: A Sweet Update on Diabetes Guidelines
This course will review the latest revisions to the American Diabetes Association (ADA) Standards of Care specifically highlighting the rising rates of obesity-related to diabetes, a pressing health concern affecting millions worldwide and often referred to as "diabesity". Learners will gain insights into nuances related to medication management and therapeutic decision-making for patients with diabetes. Content will provide guidance for reviewing and crafting patient-centered treatment strategies that holistically address glucose management while fostering improvements in cardio-metabolic, kidney, liver, and cognitive health for individuals grappling with diabetes and related comorbidities. 

Follow CEimpact on Social Media:
LinkedIn
Instagram

Insulin icodec is the first class of long-acting insulin to be administered only once a week. Join host, Jen Moulton, as she discusses the safety and efficacy of insulin icodec with guest, Geoff Wall.

The GameChanger
Insulin icodec is the first of the ultra long-acting insulins with once weekly dosing. Multiple clinical studies have suggested these pharmacokinetics work. A new meta-analysis suggests that insulin icodec is more effective than other basal insulins and at least as safe concerning hypoglycemia.

Jen Moulton, RPh
President + Founder
CEimpact

Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Wang P, Zhang Y, Xu W, et al. Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Diabetol Metab Syndr. 2024 Jan 3;16(1):3. doi: 10.1186/s13098-023-01240-5. PMID: 38172995; PMCID: PMC10763463.

https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-023-01240-5#Sec19

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Explain the chemical and structural changes that make icodec different from other basal insulins
2. Discuss the results of the meta-analysis about insulin icodec

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-043-H01-P
Initial release date: 1/29/2024
Expiration date: 1/29/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Alcohol Use Disorder (AUD) and cirrhosis are common medical conditions with significant morbidity and mortality. Join host, Geoff Wall, as he evaluates the new  American College of Gastroenterology guidelines.
 
The GameChanger
The MELD score is now preferred over the Madrey score for assessing mortality. Baclofen is the primary treatment for reducing consumption and craving in alcohol use disorder.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA, Shah VH. ACG Clinical Guideline: Alcohol-Associated Liver Disease. Am J Gastroenterol. 2024 Jan 1;119(1):30-54. doi: 10.14309/ajg.0000000000002572. Epub 2023 Sep 1. PMID: 38174913.

https://journals.lww.com/ajg/fulltext/2024/01000/acg_clinical_guideline__alcohol_associated_liver.13.aspx?context=featuredarticles&collectionid=5

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the initial treatment of a patient admitted with acute alcoholic hepatitis
2. Describe a pharmacotherapeutic plan for adjunctive treatment of alcohol use disorder

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-042-H01-P
Initial release date: 1/22/2024
Expiration date: 1/22/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Communication is ‘an essential duty’ of a pharmacist and the cornerstone of quality patient care. And yet, it continues to be one of the most common frustrations reported by preceptors when working with students and residents. Many factors may be at play, including a pandemic, as well as a digital society where so much communication happens in quick, abbreviated bytes.

On this episode, guest Christine Klein reminds us of the many facets of communication, the complex range of reasons some students and residents may struggle, and how we as mentors and teachers can support their development in this area effectively.

Host
Kathy Schott, PhD
Vice President, Education & Operations
CEimpact

Guest
Dr. Christine Klein, PharmD
Vice-Chair for Experiential Education
Clinical Associate Professor
Mercer University College of Pharmacy

Get CE: CLICK HERE TO CPE CREDIT FOR THE COURSE!

CPE Information
 
Learning Objectives
At the end of this course, preceptors will be able to:
1. Discuss the importance of strong communication skills for students and residents
2. Describe the preceptor's role in fostering professional communication

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-041-H99-P
Initial release date: 1/17/2024
Expiration date: 1/17/2027
Additional CPE details can be found here.

The speakers have no relevant financial relationships with ineligible companies to disclose.

This program has been:
Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.

Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Hyponatremia is a side effect of most diuretics but the incidence from thiazides is unknown. Join host, Geoff Wall, as he evaluates a new study from Denmark evaluating hyponatremia and thiazides.
 
The GameChanger
Thiazide diuretics are considered first-line therapy but electrolyte side effects are underevaluated. A new study suggests hyponatremia is significantly more common than previously reported, especially in the elderly.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Andersson NW, Wohlfahrt J, Feenstra B, et al. Cumulative Incidence of Thiazide-Induced Hyponatremia: A Population-Based Cohort Study. Ann Intern Med. 2023 Dec 19. doi: 10.7326/M23-1989. Epub ahead of print. PMID: 38109740.

https://www.acpjournals.org/doi/abs/10.7326/M23-1989?journalCode=aim

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the use of thiazides in hypertension and their adverse effects
2. Assess the strengths and weaknesses of the Andersson et al study

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-032-H01-P
Initial release date: 1/15/2024
Expiration date: 1/15/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Sickle cell disease (SCD) is a devastating medical condition causing pain, fatigue, and early mortality. Join host, Geoff Wall, as he evaluates a new gene therapy via CRISPR that may cure SCD.
 
The GameChanger
CRISPR is a new method to develop targeted gene editing treatments. Lovo-cel is the first FDA-approved therapy and may treat sickle cell disease (SCD) - for only $2 million.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
FDA Approval. https://www.fda.gov/vaccines-blood-biologics/lyfgenia.

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss what CRISPR is and how it can be used to treat diseases
2. Describe the use of lovotibeglogene autotemcel (lovo-cel) for sickle cell disease and its safety and efficacy data

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-031-H01-P
Initial release date: 1/8/2024
Expiration date: 1/8/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Atrial fibrillation is the most common clinical arrhythmia. The newest guidelines have significant changes in diagnosis, assessment, and treatment. Join host, Geoff Wall, with guest Matt Boyd, as they evaluate the pharmacotherapy changes in the new guidelines in this two-part episode.

The GameChanger
Rate and rhythm control medications largely have the same clinical outcomes. Patients with heart failure with reduced ejection fraction should try rhythm control first. Monitoring is key for atrial fibrillation pharmacotherapy.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health

Guest
Mathew Boyd, PharmD
Clinical Pharmacist
Unity Point

Reference
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023 Nov 23:S0735-1097(23)06465-3. doi: 10.1016/j.jacc.2023.08.017. Epub ahead of print. PMID: 38043043.

https://www.jacc.org/doi/10.1016/j.jacc.2023.08.017

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss rate versus rhythm control in patients with atrial fibrillation
2. Develop a monitoring plan and selection of medications in rhythm control

0.05 CEU/0.5 Hr
UAN: 0107-0000-24-030-H01-P
Initial release date: 1/5/2024
Expiration date: 1/5/2025
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Atrial fibrillation is the most common clinical arrhythmia. The newest guidelines have significant changes in diagnosis, assessment, and treatment. Join host, Geoff Wall, as he evaluates the first half of the guidelines in this two-part episode.

The GameChanger
Different stratifying types of atrial fibrillation no longer exist. Additionally, left atrial occlusive devices are now recommended as first-line therapy for the prevention of stroke, though anticoagulants are the treatment of choice.
 
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
 
Reference
Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2023 Nov 23:S0735-1097(23)06465-3. doi: 10.1016/j.jacc.2023.08.017. Epub ahead of print. PMID: 38043043.

https://www.jacc.org/doi/10.1016/j.jacc.2023.08.017

Pharmacist Members, REDEEM YOUR CPE HERE!
 
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)


CPE Information
 
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe new definitions of atrial fibrillation and risk factors for stroke
2. Discuss mechanical prevention of stroke in high risk patients

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-401-H01-P
Initial release date: 12/25/2023
Expiration date: 12/25/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Join Ashlee as she talks with Ina, the Director of Clinical Operations at RxGenomix, about the fascinating world of pharmacogenomics. Throughout this episode, Ashlee and Ina get into the nitty-gritty of pharmacogenomic testing - a game-changer in ensuring the right medication is administered to the right patient at the right time and dose.

Listen to this episode to equip yourself with the knowledge to grasp the potential and significance of pharmacogenomics in patient care. Whether a healthcare professional or simply curious, it's time to step into the future of personalized medicine.

In this episode, the two discuss:
- Pharmacogenomics & their implications
- The role genetics play in influencing medication responses
- Integrating pharmacogenomics into routine patient care
- The future of pharmacogenomics

Dr. Ina Liko received her Doctor of Pharmacy degree at the University of Illinois at Chicago where she was initially exposed to pharmacogenomics. She then completed a clinical residency program at Monroe Clinic where her research project was focused on the implementation of pharmacogenomics. After this initial exposure to the clinical application of pharmacogenomics, she gained experience in implementing it in a larger scale by completing a fellowship in the Clinical Implementation of Pharmacogenomics at the University of Colorado where she was exposed to a systematic approach of implementing pharmacogenomics in various therapeutic classes. Dr. Liko now serves as the Director of Clinical Pharmacogenomics Operations at RxGenomix where she works collaboratively in a multidisciplinary team leading the clinical operations.

To learn more about CEimpact's By Design memberships, click here.
To learn more about the CEimpact Advanced PGx training, click here

Follow CEimpact on Social Media:
LinkedIn
Instagram

Utter the words "Artificial Intelligence" to other preceptors and pharmacy faculty, and you might get a reaction that ranges anywhere from fear and anxiety to excitement. In this insightful discussion, we explore the fundamental question of what AI is and its diverse application in shaping the landscape of pharmacy education. Guest Tim Aungst delves into the challenges surrounding student and resident access to AI tools, shedding light on the challenges and opportunities that access brings.
 
Host
Kathy Schott, PhD
Vice President, Education & Operations
CEimpact

Guest
Timothy Dy Aungst, PharmD, RPh
Associate Professor of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences

Get CE: CLICK HERE TO CPE CREDIT FOR THE COURSE!

CPE Information
 
Learning Objectives
At the end of this course, preceptors will be able to:
1. List a primary advantage of using artificial intelligence (AI)
2. Discuss ways in which access to AI should inform teaching strategies.

0.05 CEU/0.5 Hr
UAN: 0107-0000-23-402-H99-P
Initial release date: 12/20/2023
Expiration date: 12/20/2024
Additional CPE details can be found here.

Dr. Schott has no relevant financial relationships with ineligible companies to disclose.

Dr. Aungst reports he is a consultant for Otsuka and an advisor for Digital Therapeutics Alliance. All relevant financial relationships have been mitigated.

This program has been:
Approved by the Minnesota Board of Pharmacy as education for Minnesota pharmacy preceptors.

Reviewed by the Texas Consortium on Experiential Programs and has been designated as preceptor education and training for Texas preceptors.

Follow CEimpact on Social Media:
LinkedIn
Instagram